Reference priceEUR €577.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Novantron Injektionsl sung |
|---|---|
| Manufacturer | MEDA Pharma GmbH |
| Prescription required | Yes |
Novantron Injektionsl sung 10mg/5ml (Mitoxantrone)
Mitoxantrone
Description
Novantron Injektionsl sung 10mg/5ml (Mitoxantrone) is a medicine catalog record in the MediPriceHub database. Active ingredient: Mitoxantrone. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: MEDA Pharma GmbH. Therapeutic category: Medicine Library > Oncology Medicines > Testicular Cancer Medicines. Pack information: 10 / 5. Origin country or market: Switzerland. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
Mitoxantrone injection, USP (concentrate) is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone injection, USP (concentrate) is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone injection, USP (concentrate) in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone injection, USP (concentrate) in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.How to Use
MEDA Pharma GmbH Metastasierendes Mamma-Karzinom, Monotherapie: Kombinationschemotherapie:Specification
Active ingredient: Mitoxantrone. Pack size: 10 / 5. Pack unit: bottle. Manufacturer: MEDA Pharma GmbH. Origin country: Switzerland. Source category: Medicine Library > Oncology Medicines > Testicular Cancer Medicines. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.Diese Angaben dienen nur als Referenz. Lassen Sie sich vor der Anwendung eines Medikaments von medizinischem Fachpersonal beraten.